Official opening of Scottish Centre for Regenerative Medicine and bio-incubator facility, Nine, marks milestone in the growth of Edinburgh BioQuarter.
Research into conditions such as multiple sclerosis and heart and liver disease will benefit from multi-million stem cell research and life sciences facilities due to be opened today (Monday, 28th May) by HRH, the Princess Royal.
The Princess Royal unveiled plaques this afternoon at the £54 million Scottish Centre for Regenerative Medicine (SCRM) and £24 million bio-incubator facility, Nine, in Edinburgh.
The University of Edinburgh’s Scottish Centre for Regenerative Medicine will carry out cutting-edge stem cell research to help find therapies for
Academic institutions are in a much better position than pharmaceutical companies to make the best decisions about which therapies deserve further development. That was the underlying message from a pair of Stanford researchers at a panel on stem cell science at last weekend’s Association of Health Care Journalism 2015 conference.
“There’s an inherent flaw in our system,” said Irving Weissman, MD, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. “Companies are driven by the desire for profits rather than the desire to find the best therapy, and they often give up on discoveries too early.”
Bioheart Inc, a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announces an update on the phase I safety trial using adipose derived cells.
Approximately four years ago in April, 2010, Bioheart initiated a study using adipose derived stem cells (AdipoCell(TM)) in congestive heart failure patients. In collaboration with the Regenerative Medicine Institute of Tijuana, Mexico, five congestive heart failure patients were successfully treated in the initial pilot trial at Hospital Angeles Tijuana. Patients underwent a mini-lipoaspiration procedure where 60ccs of fat were removed.
This fat was processed to obtain the stromal vascular fraction (SVF) which
Three teams of USC stem cell researchers have won a coveted prize — the opportunity to test 3,000 drug candidates or chemicals for the potential to help patients. Two teams will focus their efforts on cancer; the third will search for ways to accelerate the healing of large bone fractures.
The free screens will take place at the Choi Family Therapeutic Screening Facility, part of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC. Andrew McMahon, director of the stem cell research center, is sponsoring the bone repair project, and Stephen Gruber, director of
A Harvard-led team is the first to demonstrate the ability to use low-power light to trigger stem cells inside the body to regenerate tissue, an advance they reported in Science Translational Medicine. The research, led by David J. Mooney, Robert P. Pinkas Family Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences (SEAS), lays the foundation for a host of clinical applications in restorative dentistry and regenerative medicine more broadly, such as wound healing, bone regeneration, and more.
The team used a low-power laser to trigger human dental stem cells to form dentin, the hard tissue that